RxDoctor Payments Data

Ray Douglas, MD

Family Medicine · Milton, PANPI 1184643488

Payments from drug & device makers

$3,617in general payments, 2019–2025

Across 193 payments — averaging $18.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$734
  • Lilly USA, LLC$634
  • Novo Nordisk$403
  • AstraZeneca$377
  • GSK$263
  • Boehringer Ingelheim$213
  • plus $993 from 14 others

What the payments were for

  • Food & beverage$3,617100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,617 in reported general payments places this provider in the 80th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$121,683
Medicare patients
300
Services billed
2,241

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban126$119,947
JardianceEmpagliflozin118$109,287
OzempicSemaglutide72$72,997
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$32,773
XareltoRivaroxaban39$27,007
ProliaDenosumab15$24,955
Stiolto RespimatTiotropium Br/Olodaterol Hcl39$23,333
Breo ElliptaFluticasone/Vilanterol33$21,446
TrulicityDulaglutide16$20,103
ErythromycinErythromycin Base11$11,957
Spiriva RespimatTiotropium Bromide16$10,989
Novolog FlexpenInsulin Aspart24$10,674
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr19$10,300
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp34$10,085
MyrbetriqMirabegron17$8,821

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat$213$143,609173 claims
PfizerEliquis$212$119,947126 claims
Novo NordiskOzempic$403$72,99772 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$263$70,629111 claims
Johnson & JohnsonXarelto$188$27,00739 claims
AmgenProlia$189$24,95515 claims
Lilly USA, LLCTrulicity$634$20,10316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Milton

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →